Skip to content

13F-HR filed by Cormorant Asset Management, LP

Cormorant Asset Management, LP filed this 13F-HR for the quarter ended 2023-12-31, filed 2024-02-14, with 48 holding rows worth $2,093,868,226.

Accession
0001583977-24-000001
Filed
2024-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2023

A holdings report, 48 entries on the cover page, a total value of $2,093,868,226 stated on the cover page (in dollars after the unit check, H1), rows summing to $2,093,868,226 with VALUE read as dollars as filed, 13F file number 028-15949. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD61559X104Stock8,494,151$512,961,779dollars as filed
AMBRX BIOPHARMA INC641871108COM11,231,000$159,929,440dollars as filed
EYEPOINT INC COM NEW30233G209Stock6,038,235$139,543,611dollars as filed
BRIDGEBIO PHARMA INC10806X102COM3,344,179$135,004,506dollars as filed
ARCELLX INC COMMON STOCK03940C100Stock1,700,000$94,350,000dollars as filed
RAYZEBIO INC75525N107COM1,213,478$75,441,927dollars as filed
BIOMEA FUSION INC09077A106CMN3,570,872$51,849,061dollars as filed
IMMUNOVANT INC45258J102COM1,165,000$49,081,450dollars as filed
ALPINE IMMUNE SCIENCES INC02083G100COM2,550,000$48,603,000dollars as filed
PHARVARIS NVN69605108COMMON STOCK1,711,460$48,006,453dollars as filed
ALX ONCOLOGY HOLDINGS INC00166B105COMMON STOCK3,142,079$46,785,556dollars as filed
TARSUS PHARMACEUTICALS INC87650L103COMMON STOCK2,221,422$44,983,796dollars as filed
CYMABAY THERAPEUTICS INC23257D103COM1,800,000$42,516,000dollars as filed
VAXCYTE INC COM92243G108Stock665,000$41,762,000dollars as filed
CRINETICS PHARMACEUTICALS INC COM22663K107Stock1,150,000$40,917,000dollars as filed
APELLIS PHARMACEUTICALS INC03753U106COM625,000$37,412,500dollars as filed
MARINUS PHARMACEUTICALS INC56854Q200COM NEW3,250,000$35,327,500dollars as filed
AUTOLUS THERAPEUTICS PLC SPON05280R100COM5,450,000$35,098,000dollars as filed
OLEMA PHARMACEUTICALS INC68062P106COM2,456,800$34,468,904dollars as filed
IMMUNEERING CORP45254E107CLASS A COM4,204,364$30,902,075dollars as filed
EDGEWISE THERAPEUTICS INC28036F105COM2,551,989$27,918,760dollars as filed
AEROVATE THERAPEUTICS INC008064107COM1,211,696$27,420,680dollars as filed
CARGO THERAPEUTICS INC COM14179K101Stock1,182,563$27,376,333dollars as filed
SYNDAX PHARMACEUTICALS INC87164F105COM1,175,000$25,391,750dollars as filed
KORRO BIO INC500946108COMMON STOCK529,170$25,363,118dollars as filed
RHYTHM PHARMACEUTICALS INC76243J105COM550,000$25,283,500dollars as filed
ABIVAX SA-00370M103SPONSORED ADS2,130,000$22,791,000dollars as filed
HARPOON THERAPEUTICS INC41358P205COM2,349,060$22,550,934dollars as filed
SPYRE THERAPEUTICS INC00773J202COM NEW937,080$20,165,962dollars as filed
INSMED INC COM PAR $.01457669307Stock575,000$17,819,250dollars as filed
IDEAYA BIOSCIENCES INC COM45166A102Stock450,000$16,011,000dollars as filed
AXONICS INC05465P101COM250,000$15,557,500dollars as filed
NEUROGENE INC64135M105COMMON STOCK746,180$14,460,968dollars as filed
LONGBOARD PHARMACEUTICALS IN54300N103COM2,353,141$14,189,440dollars as filed
PRAXIS PRECISION MEDICINES I74006W207COM NEW633,345$14,110,927dollars as filed
ROCKET PHARMACEUTICALS INC77313F106COM450,000$13,486,500dollars as filed
RAPT THERAPEUTICS INC75382E109COM496,750$12,344,238dollars as filed
DISC MEDICINE INC COM254604101Stock125,000$7,220,000dollars as filed
STOKE THERAPEUTICS INC86150R107COM1,087,807$5,721,865dollars as filed
EDITAS MEDICINE INC28106W103COM500,000$5,065,000dollars as filedput
VERVE THERAPEUTICS INC92539P101COM350,000$4,879,000dollars as filed
LANTHEUS HLDGS INC516544103COM75,000$4,650,000dollars as filed
CENTESSA PHARMACEUTICALS PLC152309100SPONSORED ADS561,600$4,470,336dollars as filed
BIOHAVEN LTDG1110E107COM81,963$3,508,016dollars as filed
GH RESEARCH PLC ORDINARY SHARESG3855L106Stock593,043$3,439,649dollars as filed
VYNE THERAPEUTICS INC92941V308COM1,394,336$3,248,803dollars as filed
BIOATLA INC09077B104COM1,181,115$2,905,543dollars as filed
NEUMORA THERAPEUTICS INC.640979100COM92,293$1,573,596dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001583977-24-000001this filing2024-02-14acceptance time not in the bulk data set